Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond

Nature Reviews Drug Discovery

Volumn 16, Issue 8, 2017, Pages 565-586

  Boldescu, Veaceslav ^a,b   Behnam, Mira A M ^a   Vasilakis, Nikos ^c   Klein, Christian D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INSTITUTE OF CHEMISTRY   (Moldova)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2 OXO LYCORINE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIVIRUS AGENT; BALAPIRAVIR; BREQUINAR; CALNEXIN; CALRETICULIN; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; CYCLOSPORIN; DASATINIB; DIHYDROOROTATE DEHYDROGENASE; EFLORNITHINE; GALIDESIVIR; LYCORINE; MEVINOLIN; MITOCHONDRIAL DNA; NELFINAVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; NSC 12155; NUCLEOSIDE; PALMATINE; SOFOSBUVIR; ST 148; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRAL PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; BIOSYNTHESIS; CLIMATE CHANGE; CONTROLLED STUDY; DENGUE; DRUG MECHANISM; DRUG STRUCTURE; EBOLAVIRUS; FLAVIVIRIDAE INFECTION; FLAVIVIRUS; GENE MUTATION; HUMAN; HYDROPHOBICITY; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; RNA VIRUS; TROPISM; VIRUS ENTRY; VIRUS REPLICATION; WEST NILE VIRUS; ZIKA VIRUS; ANIMAL; DRUG DESIGN; DRUG EFFECTS; FLAVIVIRUS INFECTIONS; MOLECULARLY TARGETED THERAPY; VIROLOGY; WEST NILE FEVER; ZIKA VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DRUG DESIGN; FLAVIVIRUS INFECTIONS; HUMANS; MOLECULAR TARGETED THERAPY; VIRUS INTERNALIZATION; VIRUS REPLICATION; WEST NILE FEVER; ZIKA VIRUS INFECTION;

EID: 85016393116     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2017.33     Document Type: Review

References (327)

1. Meanwell, N. A. 2015 Philip S. Portoghese medicinal chemistry lectureship. Curing hepatitis C virus infection with direct-acting antiviral agents: The arc of a medicinal chemistry triumph. J. Med. Chem. 59, 7311-7351 (2016).
2. Theiler, M., Smith, H. H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787-800 (1937).
3. Fernandez-Garcia, M.-D., Mazzon, M., Jacobs, M., Amara, A. Pathogenesis of flavivirus infections: Using and abusing the host cell. Cell Host Microbe 5, 318-328 (2009).
4. Sips, G. J., Wilschut, J., Smit, J. M. Neuroinvasive flavivirus infections. Rev. Med. Virol. 22, 69-87 (2012).
5. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
6. Zanluca, C. et al. First report of autochthonous transmission of Zika virus in Brazil. Mem. Inst. Oswaldo Cruz 110, 569-572 (2015).
7. Mackenzie, J. S., Gubler, D. J., Petersen, L. R. Emerging flaviviruses: The spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98-S109 (2004).
8. Weaver, S. C., Barrett, A. D. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat. Rev. Microbiol. 2, 789-801 (2004).
9. Weaver, S. C. et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 130, 69-80 (2016).
10. Hadinegoro, S. R. et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195-1206 (2015
11. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005).
12. Barrows, N. J. et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 20, 259-270 (2016).
13. Shum, D. et al. High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev. Technol. 8, 553-570 (2010).
14. Idris, F., Muharram, S. H., Diah, S. Glycosylation of dengue virus glycoproteins and their interactions with carbohydrate receptors: Possible targets for antiviral therapy. Arch. Virol. 161, 1751-1760 (2016).
15. Choy, M. M. et al. Proteasome inhibition suppresses dengue virus egress in antibody dependent infection. PLoS Negl. Trop. Dis. 9, e0004058 (2015).
16. Holmes, E. C. The Evolution and Emergence of RNA Viruses (Oxford Univ. Press, 2009).
17. Metzner, K. J. et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients. Clin. Infect. Dis. 48, 239-247 (2009).
18. Beck, A. et al. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J. Infect. Dis. 209, 334-344 (2014).
19. Selvey, L. A., Speers, D. J., Smith, D. W. Long-term outcomes of Murray Valley encephalitis cases in Western Australia: What have we learnt Intern. Med. J. 46, 193-201 (2016).
20. Oehler, E. et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill. 19, 20720 (2014).
21. Fontes, C. A. P., dos Santos, A. A. S. D., Marchiori, E. Magnetic resonance imaging findings in Guillain-Barré syndrome caused by Zika virus infection. Neuroradiology 58, 837-838 (2016).
22. McMahon, A. W. et al. Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases. Vaccine 25, 1727-1734 (2007).
23. Puccioni-Sohler, M. et al. Neurologic dengue manifestations associated with intrathecal specific immune response. Neurology 73, 1413-1417 (2009).
24. McMinn, P. C. The molecular basis of virulence of the encephalitogenic flaviviruses. J. Gen. Virol. 78, 2711-2722 (1997).
25. Ravi, V. et al. Persistence of Japanese encephalitis virus in the human nervous system. J. Med. Virol. 40, 326-329 (1993).
26. Penn, R. G. et al. Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin. Infect. Dis. 42, 680-683 (2006).
27. Paessler, S., Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 8, 411-440 (2013).
28. de Oliveira, W. K. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy-Brazil, 2015. MMWR Morb. Mortal. Wkly Rep. 65, 242-247 (2016).
29. Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro-preliminary report. N. Engl. J. Med. 375, 2321-2334 (2016).
30. Cauchemez, S. et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: A retrospective study. Lancet 387, 2125-2132 (2016).
31. Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081-1091 (2016).
32. Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267-271 (2016).
33. Habu, A., Murakami, Y., Ogasa, A., Fujisaki, Y. Disorder of spermatogenesis and viral discharge into semen in boars infected with Japanese encephalitis virus (author's transl). Uirusu 27, 21-26 (in Japanese) (1977).
34. Musso, D. et al. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21, 359-361 (2015).
35. Mansuy, J. M. et al. Zika virus: High infectious viral load in semen, a new sexually transmitted pathogen. Lancet Infect. Dis. 16, 405 (2016).
36. Rossi, S. L. et al. Characterization of a novel murine model to study Zika virus. Am. J. Trop. Med. Hyg. 94, 1362-1369 (2016).
37. Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720-730 (2016).
38. Prisant, N. et al. Zika virus in the female genital tract. Lancet Infect. Dis. 16, 1000-1001 (2016).
39. Foy, B. D. et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17, 880-882 (2011).
40. Frank, C. et al. Sexual transmission of Zika virus in Germany, April 2016. Euro Surveill. 21, 30252 (2016).
41. Deckard, D. T. Male-to-male sexual transmission of Zika virus-Texas, January 2016. MMWR Morb. Mortal. Wkly Rep. 65, 372-374 (2016).
42. Barthel, A. et al. Breast milk as a possible route of vertical transmission of dengue virus Clin. Infect. Dis. 57, 415-417 (2013).
43. Kuhn, S., Twele-Montecinos, L., MacDonald, J., Webster, P., Law, B. Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183, E243-E245 (2011).
44. Centers for Disease Control and Prevention. Possible West Nile virus transmission to an infant through breast-feeding-Michigan, 2002. MMWR Morb. Mortal. Wkly Rep. 51, 877-878 (2002).
45. Dupont-Rouzeyrol, M., Biron, A., O'Connor, O., Huguon, E., Descloux, E. Infectious Zika viral particles in breastmilk. Lancet 387, 1051 (2016).
46. Musso, D. et al. Detection of Zika virus in saliva. J. Clin. Virol. 68, 53-55 (2015).
47. De Clercq, E., Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695-747 (2016).
48. Klema, V. J., Padmanabhan, R., Choi, K. H. Flaviviral replication complex: Coordination between RNA synthesis and 5-RNA capping. Viruses 7, 4640-4656 (2015).
49. Chambers, T. J., Nestorowicz, A., Rice, C. M. Mutagenesis of the yellow fever virus NS2B/3 cleavage site: Determinants of cleavage site specificity and effects on polyprotein processing and viral replication. J. Virol. 69, 1600-1605 (1995).
50. Li, J. et al. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 280, 28766-28774 (2005).
51. Chappell, K. J., Stoermer, M. J., Fairlie, D. P., Young, P. R. Insights to substrate binding and processing by West Nile virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J. Biol. Chem. 281, 38448-38458 (2006).
52. Stoermer, M. J. et al. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J. Med. Chem. 51, 5714-5721 (2008).
53. Behnam, M. A. M., Graf, D., Bartenschlager, R., Zlotos, D. P., Klein, C. D. Discovery of nanomolar dengue and West Nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue. J. Med. Chem. 58, 9354-9370 (2015).
54. Nitsche, C. et al. Peptide-boronic acid inhibitors of flaviviral proteases: Medicinal chemistry and structural biology. J. Med. Chem. 60, 511-516 (2017).
55. Chu, J. J. et al. Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay. Antiviral Res. 118, 68-74 (2015).
56. Nitsche, C. et al. Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture. J. Med. Chem. 56, 8389-8403 (2013).
57. Peterlin-Mašic, L., Kikelj, D. Arginine mimetics. Tetrahedron 57, 7073-7105 (2001).
58. Gustafsson, D. et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101, 171-181 (2001).
59. Bazan, J. F., Fletterick, R. J. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171, 637-639 (1989).
60. Falgout, B., Pethel, M., Zhang, Y. M., Lai, C. J. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65, 2467-2475 (1991).
61. Chambers, T. J., Grakoui, A., Rice, C. M. Processing of the yellow fever virus nonstructural polyprotein: A catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J. Virol. 65, 6042-6050 (1991).
62. Erbel, P. et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13, 372-373 (2006).
63. Su, X.-C. et al. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease. PLoS Negl. Trop. Dis. 3, e561 (2009).
64. Noble, C. G., Seh, C. C., Chao, A. T., Shi, P. Y. Ligand-bound structures of the dengue virus protease reveal the active conformation. J. Virol. 86, 438-446 (2012).
65. Chen, W.-N., Loscha, K. V., Nitsche, C., Graham, B., Otting, G. The dengue virus NS2B-NS3 protease retains the closed conformation in the complex with BPTI. FEBS Lett. 588, 2206-2211 (2014).
66. Gupta, G., Lim, L., Song, J. NMR and MD studies reveal that the isolated dengue NS3 protease is an intrinsically disordered chymotrypsin fold which absolutely requests NS2B for correct folding and functional dynamics. PLoS ONE 10, e0134823 (2015).
67. Lei, J. et al. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science 353, 503-505 (2016).
68. Steuer, C., Heinonen, K. H., Kattner, L., Klein, C. D. Optimization of assay conditions for dengue virus protease: Effect of various polyols and nonionic detergents. J. Biomol. Screen. 14, 1102-1108 (2009).
69. Nitsche, C., Klein, C. D. in Antiviral Methods and Protocols (ed. Gong, E. Y.) 221-236 (Humana Press, 2013).
70. Nitsche, C., Holloway, S., Schirmeister, T., Klein, C. D. Biochemistry and medicinal chemistry of the dengue virus protease. Chem. Rev. 114, 11348-11381 (2014).
71. Nall, T. A. et al. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J. Biol. Chem. 279, 48535-48542 (2004).
72. Adamek, R. N., Maniquis, R. V., Khakoo, S., Bridges, M. D., Salzameda, N. T. A FRET-based assay for the discovery of West Nile virus NS2B-NS3 protease inhibitors. Bioorg. Med. Chem. Lett. 23, 4848-4850 (2013).
73. Yin, Z. et al. Peptide inhibitors of dengue virus NS3 protease. Part 1: Warhead. Bioorg. Med. Chem. Lett. 16, 36-39 (2006).
74. Yin, Z. et al. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16, 40-43 (2006).
75. Knox, J. E. et al. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J. Med. Chem. 49, 6585-6590 (2006).
76. Behnam, M. A. M., Nitsche, C., Vechi, S. M., Klein, C. D. C-Terminal residue optimization and fragment merging: Discovery of a potent peptide-hybrid inhibitor of dengue protease. ACS Med. Chem. Lett. 5, 1037-1042 (2014).
77. Bastos Lima, A. et al. Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids. Bioorg. Med. Chem. 23, 5748-5755 (2015).
78. Weigel, L. F., Nitsche, C., Graf, D., Bartenschlager, R., Klein, C. D. Phenylalanine and phenylglycine analogs as arginine mimetics in dengue protease inhibitors. J. Med. Chem. 58, 7719-7733 (2015).
79. Jia, F., Zou, G., Fan, J., Yuan, Z. Identification of palmatine as an inhibitor of West Nile virus. Arch. Virol. 155, 1325-1329 (2010).
80. Yang, C. C. et al. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob. Agents Chemother. 55, 229-238 (2011).
81. Yang, C. C. et al. A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease. Antimicrob. Agents Chemother. 58, 110-119 (2014).
82. Bhakat, S. et al. Reaching beyond HIV/HCV: Nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus. RSC Adv. 5, 85938-85949 (2015).
83. Rice, C. et al. Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution. Science 229, 726-733 (1985).
84. Malet, H. et al. Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J. Biol. Chem. 282, 10678-10689 (2007).
85. Yap, T. L. et al. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J. Virol. 81, 4753-4765 (2007).
86. Zhao, B. et al. Structure and function of the Zika virus full-length NS5 protein. Nat. Commun. 8, 14762 (2017).
87. Wang, B. et al. The structure of Zika virus NS5 reveals a conserved domain conformation. Nat. Commun. 8, 14763 (2017).
88. Godoy, A. S. et al. Crystal structure of Zika virus NS5 RNA-dependent RNA polymerase. Nat. Commun. 8, 14764 (2017).
89. Malet, H. et al. The flavivirus polymerase as a target for drug discovery. Antiviral Res. 80, 23-35 (2008).
90. Olsen, D. B. et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48, 3944-3953 (2004).
91. Yin, Z. et al. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl Acad. Sci. USA 106, 20435-20439 (2009).
92. Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405 (2014).
93. Vernachio, J. H. et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob. Agents Chemother. 55, 1843-1851 (2011).
94. Nguyen, N. M. et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J. Infect. Dis. 207, 1442-1450 (2013).
95. De Burghgraeve, T. et al. 3, 5Di-O-trityluridine inhibits in vitro flavivirus replication. Antiviral Res. 98, 242-247 (2013).
96. Eyer, L. et al. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. Antiviral Res. 133, 119-129 (2016).
97. Zmurko, J. et al. The viral polymerase inhibitor 7-deaza-2-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10, e0004695 (2016).
98. Eyer, L. et al. Nucleoside inhibitors of Zika virus. J. Infect. Dis. 214, 707-711 (2016).
99. Schul, W., Liu, W., Xu, H.-Y., Flamand, M., Vasudevan, S. G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195, 665-674 (2007).
100. Latour, D. R. et al. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-D-2-ethynyl-7-deaza-adenosine triphosphate. Antiviral Res. 87, 213-222 (2010).
101. Chen, Y.-L. et al. Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob. Agents Chemother. 54, 2932-2939 (2010).
102. Lo, M. K., Shi, P.-Y., Chen, Y.-L., Flint, M., Spiropoulou, C. F. In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses. Antiviral Res. 130, 46-49 (2016).
103. Chen, Y.-L., Yokokawa, F., Shi, P.-Y. The search for nucleoside/nucleotide analog inhibitors of dengue virus. Antiviral Res. 122, 12-19 (2015).
104. Julander, J. G. et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob. Agents Chemother. 58, 6607-6614 (2014).
105. Taylor, R. et al. BCX4430-a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J. Infect. Public Health 9, 220-226 (2016).
106. Golitsina, N. L., Danehy, F. T. Jr, Fellows, R., Cretton-Scott, E., Standring, D. N. Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2-C-methyl-cytidine to its 5-monophosphate metabolite. Antiviral Res. 85, 470-481 (2010).
107. Berke, J. M. et al. Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55, 3812-3820 (2011).
108. Sofia, M. J. in Antiviral Agents Vol. 67 (ed. de Clercq, E.) 39-73 (Academic Press, 2013).
109. Sofia, M. J. et al. Discovery of a-D-2-deoxy-2-fluo ro-2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202-7218 (2010).
110. Chen, Y.-L. et al. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J. Virol. 88, 1740-1747 (2014).
111. Gao, W. Y., Shirasaka, T., Johns, D. G., Broder, S., Mitsuya, H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91, 2326-2333 (1993).
112. Kohler, J. J., Lewis, W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ. Mol. Mutagen. 48, 166-172 (2007).
113. Coats, S. J. et al. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res. 102, 119-147 (2014).
114. Yeo, K. L. et al. Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob. Agents Chemother. 59, 2086-2093 (2015).
115. Nelson, J., Roe, K., Orillo, B., Shi, P.-Y., Verma, S. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Res. 122, 39-45 (2015).
116. Lim, S. P. et al. Potent allosteric dengue virus NS5 polymerase inhibitors: Mechanism of action and resistance profiling. PLoS Pathog. 12, e1005737 (2016).
117. Eltahla, A. A., Luciani, F., White, P. A., Lloyd, A. R., Bull, R. A. Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 7, 5206-5224 (2015).
118. Taguwa, S. et al. Defining Hsp70 subnetworks in dengue virus replication reveals key vulnerability in Flavivirus infection. Cell 163, 1108-1123 (2015).
119. Smit, J., Moesker, B., Rodenhuis-Zybert, I., Wilschut, J. Flavivirus cell entry and membrane fusion. Viruses 3, 160-171 (2011).
120. Zhang, Y. et al. Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618 (2004).
121. Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C., Harrison, S. C. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375, 291-298 (1995).
122. Modis, Y., Ogata, S., Clements, D., Harrison, S. C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl Acad. Sci. USA 100, 6986-6991 (2003).
123. Modis, Y., Ogata, S., Clements, D., Harrison, S. C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319 (2004).
124. Kanai, R. et al. Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol. 80, 11000-11008 (2006).
125. Nybakken, G. E., Nelson, C. A., Chen, B. R., Diamond, M. S., Fremont, D. H. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80, 11467-11474 (2006).
126. Wang, Q.-Y. et al. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 53, 1823-1831 (2009).
127. Kampmann, T. et al. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res. 84, 234-241 (2009).
128. Martinez, J. P., Sasse, F., Bronstrup, M., Diez, J., Meyerhans, A. Antiviral drug discovery: Broad-spectrum drugs from nature. Nat. Prod. Rep. 32, 29-48 (2015).
129. Ishag, H. Z. A. et al. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch. Virol. 158, 349-358 (2013).
130. Meuleman, P. et al. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob. Agents Chemother. 55, 5159-5167 (2011).
131. Mori, T. et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280, 9345-9353 (2005).
132. Barton, C. et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin Griffithsin in two laboratory rodent models. Antimicrob. Agents Chemother. 58, 120-127 (2014).
133. Zasloff, M. et al. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc. Natl Acad. Sci. USA 108, 15978-15983 (2011).
134. Richard, A. S. et al. Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc. Natl Acad. Sci. USA 112, 14682-14687 (2015).
135. Jemielity, S. et al. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 9, e1003232 (2013).
136. Meertens, L. et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12, 544-557 (2012).
137. Dokland, T. et al. West Nile virus core protein; tetramer structure and ribbon formation. Structure 12, 1157-1163 (2004).
138. Ma, L., Jones, C. T., Groesch, T. D., Kuhn, R. J., Post, C. B. Solution structure of dengue virus capsid protein reveals another fold. Proc. Natl Acad. Sci. USA 101, 3414-3419 (2004).
139. Samsa, M. M. et al. Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog. 5, e1000632 (2009).
140. Faustino, A. F. et al. Dengue virus capsid protein interacts specifically with very low-density lipoproteins. Nanomedicine 10, 247-255 (2012).
141. Byrd, C. M. et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob. Agents Chemother. 57, 15-25 (2013).
142. Scaturro, P. et al. Characterization of the mode of action of a potent dengue virus capsid inhibitor. J. Virol. 88, 11540-11555 (2014).
143. Zmurko, J., Neyts, J., Dallmeier, K. Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. Rev. Med. Virol. 25, 205-223 (2015).
144. Xie, X., Zou, J., Wang, Q.-Y., Shi, P.-Y. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res. 118, 39-45 (2015).
145. Miller, S., Sparacio, S., Bartenschlager, R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 281, 8854-8863 (2006).
146. Youn, S. et al. Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J. Virol. 86, 7360-7371 (2012).
147. Li, X.-D. et al. Genetic interaction between NS4A and NS4B for replication of Japanese encephalitis virus. J. Gen. Virol. 96, 1264-1275 (2015).
148. Xie, X. et al. Inhibition of dengue virus by targeting viral NS4B protein. J. Virol. 85, 11183-11195 (2011).
149. Wang, Q.-Y. et al. Discovery of dengue virus NS4B inhibitors. J. Virol. 89, 8233-8244 (2015).
150. Zou, G. et al. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384, 242-252 (2009).
151. Wang, P. et al. Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives. ChemMedChem 9, 1522-1533 (2014).
152. Luo, D. et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J. 27, 3209-3219 (2008).
153. Mastrangelo, E., Bolognesi, M., Milani, M. Flaviviral helicase: Insights into the mechanism of action of a motor protein. Biochem. Biophys. Res. Commun. 417, 84-87 (2012).
154. Lescar, J. et al. Towards the design of antiviral inhibitors against flaviviruses: The case for the multifunctional NS3 protein from dengue virus as a target. Antiviral Res. 80, 94-101 (2008).
155. Tian, H. et al. The crystal structure of Zika virus helicase: Basis for antiviral drug design. Protein Cell 7, 450-454 (2016).
156. Byrd, C. M. et al. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob. Agents Chemother. 57, 1902-1912 (2013).
157. Sweeney, N. L. et al. Benzothiazole and pyrrolone flavivirus inhibitors targeting the viral helicase. ACS Infect. Dis. 1, 140-148 (2015).
158. Mastrangelo, E. et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug. J. Antimicrob. Chemother. 67, 1884-1894 (2012).
159. Tomlinson, S. M., Watowich, S. J. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors. Antiviral Res. 93, 245-252 (2012).
160. Egloff, M.-P. et al. Structural and functional analysis of methylation and 5-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J. Mol. Biol. 372, 723-736 (2007).
161. Issur, M. et al. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 15, 2340-2350 (2009).
162. Egloff, M. P., Benarroch, D., Selisko, B., Romette, J. L., Canard, B. An RNA cap (nucleoside-2-O-)-methyltransferase in the flavivirus RNA polymerase NS5: Crystal structure and functional characterization. EMBO J. 21, 2757-2768 (2002).
163. Dong, H. et al. West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J. Virol. 82, 4295-4307 (2008).
164. Chung, K. Y. et al. Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2-O methyltransferase activity in dengue virus. Virology 402, 52-60 (2010).
165. Dong, H. et al. Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase. J. Biol. Chem. 285, 32586-32595 (2010).
166. Lim, S. P. et al. Small molecule inhibitors that selectively block dengue virus methyltransferase. J. Biol. Chem. 286, 6233-6240 (2011).
167. Vernekar, S. K. V. et al. 5-silylated 3-1, 2, 3-triazolyl thymidine analogues as inhibitors of West Nile virus and dengue virus. J. Med. Chem. 58, 4016-4028 (2015).
168. Brecher, M. et al. Identification and characterization of novel broad-spectrum inhibitors of the flavivirus methyltransferase. ACS Infect. Dis. 1, 340-349 (2015).
169. Marques, R. E. et al. Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. Immunology 145, 583-596 (2015).
170. Larena, M., Regner, M., Lobigs, M. The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS ONE 7, e44834 (2012).
171. Glass, W. G. et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087-1098 (2005).
172. Courageot, M.-P., Frenkiel, M.-P., Dos Santos, C. D., Deubel, V., Desprès, P.-Glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74, 564-572 (2000).
173. Zhao, X. et al. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob. Agents Chemother. 59, 206-216 (2015).
174. Stavale, E. J., Vu, H., Sampath, A., Ramstedt, U., Warfield, K. L. In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar uv-4. PLoS ONE 10, e0121662 (2015).
175. Plummer, E. et al. Dengue virus evolution under a host-targeted antiviral. J. Virol. 89, 5592-5601 (2015).
176. Fischl, M. A. et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 Infection and 200-500 CD4 cells/mm. J. Acquir. Immune Defic. Syndr. 7, 139-147 (1994).
177. Durantel, D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs 10, 860-870 (2009).
178. Whitby, K. et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79, 8698-8706 (2005).
179. Rathore, A. P. et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 92, 453-460 (2011).
180. Watanabe, S. et al. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy. Antiviral Res. 127, 10-19 (2016).
181. Low, J. G. et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): A phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect. Dis. 14, 706-715 (2014).
182. Wu, S.-F. et al. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76, 3596-3604 (2002).
183. Gu, B. et al. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir. Chem. Chemother. 18, 49-59 (2007).
184. Chang, J. et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 53, 1501-1508 (2009).
185. Yu, W. et al. Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. J. Med. Chem. 55, 6061-6075 (2012).
186. Perry, S. T. et al. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res. 98, 35-43 (2013).
187. Chang, J. et al. Small molecule inhibitors of ER-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 98, 432-440 (2013).
188. Mondelli, M. U. The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both Hepatology 60, 1126-1129 (2014).
189. Reichard, O., Yun, Z. B., Sönnerborg, A., Weiland, O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J. Med. Virol. 41, 99-102 (1993).
190. Graci, J. D., Cameron, C. E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16, 37-48 (2006).
191. Crance, J. M., Scaramozzino, N., Jouan, A., Garin, D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: Antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 58, 73-79 (2003).
192. Kumar, R. et al. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin. Infect. Dis. 48, 400-406 (2009).
193. Chowers, M. Y. et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg. Infect. Dis. 7, 675-678 (2001).
194. Sbrana, E. et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am. J. Trop. Med. Hyg. 71, 306-312 (2004).
195. Colombo, G. et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res. 92, 408-414 (2011).
196. Leyssen, P. et al. A novel model for the study of the therapy of flavivirus infections using the Modoc virus. Virology 279, 27-37 (2001).
197. Minakawa, N., Matsuda, A. Mechanism-based design of inosine 5-monophosphate dehydrogenase inhibitors: Synthesis and biological activities of 5-ethynyi-1-D-ribofuranosylimidazole-4-carboxami de (EICAR) and its derivatives. Curr. Med. Chem. 6, 615-628 (1999).
198. Sebastian, L., Madhusudana, S. N., Ravi, V., Desai, A. Mycophenolic acid inhibits replication of Japanese encephalitis virus. Chemotherapy 57, 56-61 (2011).
199. Bentley, R. Mycophenolic acid: A one hundred year odyssey from antibiotic to immunosuppressant. Chem. Rev. 100, 3801-3826 (2000).
200. Qing, M. et al. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob. Agents Chemother. 54, 3686-3695 (2010).
201. First, M. R. An update on new immunosuppressive drugs undergoing preclinical and clinical trials: Potential applications in organ transplantation. Am. J. Kidney Dis. 29, 303-317 (1997).
202. Hoffmann, H.-H., Kunz, A., Simon, V. A., Palese, P., Shaw, M. L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl Acad. Sci. USA 108, 5777-5782 (2011).
203. Munier-Lehmann, H. et al. Original 2-(3-alkoxy-1H-pyrazol-1-yl) pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH). J. Med. Chem. 58, 860-877 (2015).
204. Ortiz-Rianõ, E. et al. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J. Virol. 88, 878-889 (2014).
205. Qing, M. et al. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob. Agents Chemother. 53, 3226-3235 (2009).
206. Borel, J. F. et al. In vivo pharmacological effects of ciclosporin and some analogues. Adv. Pharmacol. 35, 115-246 (1996).
207. Hansson, M. J. et al. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembr. 36, 407-413 (2004).
208. Flisiak, R. et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 49, 1460-1468 (2009).
209. Munger, J. et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 26, 1179-1186 (2008).
210. Heaton, N. S. et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc. Natl Acad. Sci. USA 107, 17345-17350 (2010).
211. Martín-Acebes, M. A., Blázquez, A.-B., De Oya, N. J., Escribano-Romero, E., Saiz, J.-C. West Nile virus replication requires fatty acid synthesis but is independent on phosphatidylinositol-4-phosphate lipids. PLoS ONE 6, e24970 (2011).
212. Loftus, T. M. et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288, 2379-2381 (2000).
213. Merino-Ramos, T. et al. Modification of the host cell lipid metabolism induced by hypolipidemic drugs targeting the acetyl coenzyme a carboxylase impairs West Nile Virus replication. Antimicrob. Agents Chemother. 60, 307-315 (2016).
214. Perera, R. et al. Dengue virus infection perturbs lipid homeostasis in infected mosquito cells. PLoS Pathog. 8, e1002584 (2012).
215. Martín-Acebes, M. A. et al. Host sphingomyelin increases West Nile virus infection in vivo. J. Lipid Res. 57, 422-432 (2016).
216. Tani, H. et al. Involvement of ceramide in the propagation of Japanese encephalitis virus. J. Virol. 84, 2798-2807 (2010).
217. Martín-Acebes, M. A. et al. The composition of West Nile virus lipid envelope unveils a role of sphingolipid metabolism in flavivirus biogenesis. J. Virol. 88, 12041-12054 (2014).
218. Poh, M. K. et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res. 93, 191-198 (2012).
219. Aktepe, T. E., Pham, H., Mackenzie, J. M. Differential utilisation of ceramide during replication of the flaviviruses West Nile and dengue virus. Virology 484, 241-250 (2015).
220. Martinez-Gutierrez, M., Correa-Londonõ, L. A., Castellanos, J. E., Gallego-Gómez, J. C., Osorio, J. E. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE 9, e87412 (2014).
221. Raung, S.-L., Chen, S.-Y., Liao, S.-L., Chen, J.-H., Chen, C.-J. Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia. Neurosci. Lett. 419, 263-268 (2007).
222. Bhattacharya, D., Best, S., Perera, R., Kuhn, R., Striker, R. Protein kinase G phosphorylates mosquito-borne flavivirus NS5. J. Virol. 83, 9195-9205 (2009).
223. de Wispelaere, M., LaCroix, A. J., Yang, P. L. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J. Virol. 87, 7367-7381 (2013).
224. Ando, T. et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int. J. Hematol. 102, 379-382 (2015).
225. Haile, W. B. et al. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol. Dis. 92, 137-143 (2016).
226. Sharma, N., Akhade, A. S., Qadri, A. Src kinases central to T-cell receptor signaling regulate TLR-activated innate immune responses from human T cells. Innate Immun. 22, 238-244 (2016).
227. Perwitasari, O., Cho, H., Diamond, M. S., Gale, M. Inhibitor of B kinase (IKK), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. J. Biol. Chem. 286, 44412-44423 (2011).
228. Mounce, B. C. et al. Inhibition of polyamine biosynthesis is a broad-spectrum strategy against RNA viruses. J. Virol. 90, 9683-9692 (2016).
229. Mounce, B. C. et al. Interferon-induced spermidine-spermine acetyltransferase and polyamine depletion restrict Zika and chikungunya viruses. Cell Host Microbe 20, 167-177 (2016).
230. Meyskens, F. L., Gerner, E. W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 5, 945-951 (1999).
231. Carocci, M., Yang, P. L. Lactimidomycin is a broad-spectrum inhibitor of dengue and other RNA viruses. Antiviral Res. 128, 57-62 (2016).
232. Brai, A. et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc. Natl Acad. Sci. USA 113, 5388-5393 (2016).
233. Sugawara, K. et al. Lactimidomycin, a new glutarimide group antibiotic. Production, isolation, structure and biological activity. J. Antibiot. (Tokyo) 45, 1433-1441 (1992).
234. Larsen, B. J. et al. Synthesis and biological evaluation of lactimidomycin and its analogues. Chemistry 21, 19159-19167 (2015).
235. Bross, P. F. et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 10, 3954-3964 (2004).
236. Lai, M. C., Sun, H. S., Wang, S. W., Tarn, W. Y. DDX3 functions in antiviral innate immunity through translational control of PACT. FEBS J. 283, 88-101 (2016).
237. Chanan-Khan, A. et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J. Clin. Oncol. 26, 4784-4790 (2008).
238. Sugiyama, R. et al. Induction of heat-shock protein 70 by prostaglandin A 1 inhibits HIV-1 Vif-mediated degradation of APOBEC3G. Antiviral Res. 99, 307-311 (2013).
239. Kumar, M. et al. Reciprocal regulation of human immunodeficiency virus-1 gene expression and replication by heat shock proteins 40 and 70. J. Mol. Biol. 410, 944-958 (2011).
240. Kim, M. Y. et al. Hsp70 and a novel axis of type I interferon-dependent antiviral immunity in the measles virus-infected brain. J. Virol. 87, 998-1009 (2013).
241. Chao, C.-H. et al. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 66, 6579-6588 (2006).
242. Raaben, M. et al. The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J. Virol. 84, 7869-7879 (2010).
243. Raaben, M., Grinwis, G. C., Rottier, P. J., de Haan, C. A. The proteasome inhibitor velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice. J. Virol. 84, 7880-7885 (2010).
244. Basler, M., Lauer, C., Beck, U., Groettrup, M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 183, 6145-6150 (2009).
245. Rossignol, J.-F. Thiazolides: A new class of antiviral drugs. Expert Opin. Drug Metab. Toxicol. 5, 667-674 (2009).
246. Korba, B. E. et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77, 56-63 (2008).
247. Rossignol, J.-F. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res. 110, 94-103 (2014).
248. Shi, Z. et al. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol. J. 11, 10 (2014).
249. Meneses, M. D. F., Duarte, R. S., Migowski, E. R., Ferreira, D. F. In vitro study of the effect of nitazoxanide on the replication of Dengue virus and yellow fever virus in Program and Abstracts of 26th International Conference on Antiviral Research (ICAR) 101 (International Society for Antiviral Research, 2013).
250. Rossignol, J. F., Elfert, A., El-Gohary, Y., Keeffe, E. B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136, 856-862 (2009).
251. Rossignol, J. F., El-Gohary, Y. M. Nitazoxanide in the treatment of viral gastroenteritis: A randomized double-blind placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 24, 1423-1430 (2006).
252. Haffizulla, J. et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 14, 609-618 (2014).
253. Santoro, M. G. et al. Thiazolides: A new class of broad-spectrum antiviral drugs targeting virus maturation. Antiviral Res. 74, A31 (2007).
254. Rossignol, J. F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M. G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284, 29798-29808 (2009).
255. Elazar, M. et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2a via protein kinase activated by double-stranded RNA activation. Gastroenterology 137, 1827-1835 (2009).
256. Trabattoni, D. et al. Thiazolides elicit anti-viral innate immunity and reduce HIV replication. Sci. Rep. 6, 27148 (2016).
257. Xu, M. et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med. 22, 1101-1107 (2016).
258. Kato, F. et al. Novel antiviral activity of bromocriptine against dengue virus replication. Antiviral Res. 131, 141-147 (2016).
259. Smith, J. L. et al. Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. J. Virol. 88, 5533-5542 (2014).
260. Boonyasuppayakorn, S., Reichert, E. D., Manzano, M., Nagarajan, K., Padmanabhan, R. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res. 106, 125-134 (2014).
261. Farias, K. J. S., Machado, P. R. L., Muniz, J. A. P. C., Imbeloni, A. A., da Fonseca, B. A. L. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Viral Immunol. 28, 161-169 (2015).
262. Wang, L.-F. et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J. Interferon Cytokine Res. 35, 143-156 (2015).
263. Tricou, V. et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl. Trop. Dis. 4, e785 (2010).
264. Borges, M. C., Castro, L. A., da Fonseca, B. A. L. Chloroquine use improves dengue-related symptoms. Mem. Inst. Oswaldo Cruz 108, 596-599 (2013).
265. Al-Bari, M. A. A. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 70, 1608-1621 (2015).
266. Cheung, Y. Y., Chen, K. C., Chen, H., Seng, E. K., Chu, J. J. H. Antiviral activity of lanatoside C against dengue virus infection. Antiviral Res. 111, 93-99 (2014).
267. Saudi, M. et al. Synthesis and evaluation of imidazole-4, 5-and pyrazine-2, 3-dicarboxamides targeting dengue and yellow fever virus. Eur. J. Med. Chem. 87, 529-539 (2014).
268. Saudi, M. et al. Synthetic strategy and antiviral evaluation of diamide containing heterocycles targeting dengue and yellow fever virus. Eur. J. Med. Chem. 121, 158-168 (2016).
269. Pattabhi, S. et al. Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway. J. Virol. 90, 2372-2387 (2016).
270. Green, R. R. et al. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway. Genom. Data 7, 290-292 (2016).
271. Tay, M. Y. F. et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 99, 301-306 (2013).
272. Forwood, J. K. et al. The 37-amino-acid interdomain of dengue virus NS5 protein contains a functional NLS and inhibitory CK2 site. Biochem. Biophys. Res. Commun. 257, 731-737 (1999).
273. Rawlinson, S. M., Pryor, M. J., Wright, P. J., Jans, D. A. CRM1-mediated nuclear export of dengue virus RNA polymerase NS5 modulates interleukin-8 induction and virus production. J. Biol. Chem. 284, 15589-15597 (2009).
274. Fraser, J. E. et al. A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. J. Infect. Dis. 210, 1780-1791 (2014).
275. Fraser, J., Wang, C., Chan, K., Vasudevan, S., Jans, D. Novel dengue virus inhibitor 4-HPR activates ATF4 independent of protein kinase R-like endoplasmic reticulum kinase and elevates levels of eIF2 phosphorylation in virus infected cells. Antiviral Res. 130, 1-6 (2016).
276. Deas, T. S. et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79, 4599-4609 (2005).
277. Stein, D. A. et al. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J. Antimicrob. Chemother. 62, 555-565 (2008).
278. Moulton, H. M., Nelson, M. H., Hatlevig, S. A., Reddy, M. T., Iversen, P. L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug. Chem. 15, 290-299 (2004).
279. Swenson, D. L. et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother. 53, 2089-2099 (2009).
280. Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378, 595-605 (2011).
281. Heald, A. E. et al. AVI-7288 for Marburg virus in nonhuman primates and humans. N. Engl. J. Med. 373, 339-348 (2015).
282. Warren, T. K. et al. Delayed time-to-treatment of an antisense morpholino oligomer is effective against lethal marburg virus infection in cynomolgus macaques. PLoS Negl. Trop. Dis. 10, e0004456 (2016).
283. Deas, T. S. et al. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51, 2470-2482 (2007).
284. Dean, C. H. et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccines against Japanese encephalitis (ChimeriVaxTM-JE) in non-human primates. Hum. Vaccin. 1, 106-111 (2005).
285. Widman, D. G. et al. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am. J. Trop. Med. Hyg. 82, 1160-1167 (2010).
286. Ito, M., Mukai, R.-Z., Takasaki, T., Kotaki, A., Kurane, I. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus. Arch. Virol. 155, 1617-1624 (2010).
287. Lee, Y.-R. et al. Suckling mice were used to detect infectious dengue-2 viruses by intracerebral injection of the full-length RNA transcript. Intervirology 48, 161-166 (2005).
288. Shresta, S., Sharar, K. L., Prigozhin, D. M., Beatty, P. R., Harris, E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80, 10208-10217 (2006).
289. Weiskopf, D. et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. 187, 4268-4279 (2011).
290. Thibodeaux, B. A. et al. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 30, 3180-3187 (2012).
291. Thibodeaux, B. A. et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res. 94, 1-8 (2012).
292. Calvert, A. E., Dixon, K. L., Delorey, M. J., Blair, C. D., Roehrig, J. T. Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain. Vaccine 32, 258-264 (2014).
293. Mota, J., Rico-Hesse, R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J. Virol. 83, 8638-8645 (2009).
294. Mota, J., Rico-Hesse, R. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS ONE 6, e20762 (2011).
295. Frias-Staheli, N. et al. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J. Virol. 88, 2205-2218 (2014).
296. Holbrook, M. R. et al. An animal model for the tickborne flavivirus-Omsk hemorrhagic fever virus. J. Infect. Dis. 191, 100-108 (2005).
297. Tigabu, B., Juelich, T., Bertrand, J., Holbrook, M. R. Clinical evaluation of highly pathogenic tick-borne flavivirus infection in the mouse model. J. Med. Virol. 81, 1261-1269 (2009).
298. Xiao, S.-Y., Guzman, H., Zhang, H., Da Rosa, A. P. T., Tesh, R. B. West Nile virus infection in the golden hamster (Mesocricetus auratus): A model for West Nile encephalitis. Emerg. Infect. Dis. 7, 714 (2001).
299. Tesh, R. B. et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 183, 1431-1436 (2001).
300. Tesh, R. B. et al. Persistent West Nile virus infection in the golden hamster: Studies on its mechanism and possible implications for other flavivirus infections. J. Infect. Dis. 192, 287-295 (2005).
301. Ferguson, N. M. et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science 353, 1033-1036 (2016).
302. López-Gatell, H., Alpuche-Aranda, C. M., Santos-Preciadob, J. I., Hernández-Ávilaa, M. Dengue vaccine: Local decisions, global consequences. Bull. World Health Organ. 94, 850 (2016).
303. Davidson, M. M., Williams, H., Macleod, J. A. Louping ill in man: A forgotten disease. J. Infect. 23, 241-249 (1991).
304. Holbrook, M. R. Kyasanur forest disease. Antiviral Res. 96, 353-362 (2012).
305. Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748 (2010).
306. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
307. Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170-177 (2015).
308. Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109-113 (2015).
309. Orlinger, K. K. et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J. Infect. Dis. 203, 1556-1564 (2011).
310. Firbas, C., Jilma, B. Product review on the JE vaccine IXIARO. Hum. Vaccin. Immunother. 11, 411-420 (2015).
311. Sabchareon, A. et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 380, 1559-1567 (2012).
312. Ishikawa, T., Yamanaka, A., Konishi, E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32, 1326-1337 (2014).
313. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102-1108 (2016).
314. Plentz, A., Jilg, W., Schwarz, T. F., Kuhr, H. B., Zent, O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur® Adults. Vaccine 27, 853-856 (2009).
315. Monath, T. P. 17D yellow fever virus vaccine. Am. J. Trop. Med. Hyg. 89, 1225 (2013).
316. Green, N., Ott, R. D., Isaacs, R. J., Fang, H. Cell-based assays to identify inhibitors of viral disease. Expert Opin. Drug Discov. 3, 671-676 (2008).
317. Payne, A. F., Binduga-Gajewska, I., Kauffman, E. B., Kramer, L. D. Quantitation of flaviviruses by fluorescent focus assay. J. Virol. Methods 134, 183-189 (2006).
318. Vasilakis, N. et al. Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors. Nat. Biotechnol. 21, 932-935 (2003).
319. Drake, J. W., Holland, J. J. Mutation rates among RNA viruses. Proc. Natl Acad. Sci. USA 96, 13910-13913 (1999).
320. Klimstra, W. B., Ryman, K. D., Johnston, R. E. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 72, 7357-7366 (1998).
321. Heil, M. L., Albee, A., Strauss, J. H., Kuhn, R. J. An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety. J. Virol. 75, 6303-6309 (2001).
322. Bernard, K. A., Klimstra, W. B., Johnston, R. E. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276, 93-103 (2000).
323. Smit, J. M. et al. Adaptation of alphaviruses to heparan sulfate: Interaction of Sindbis and Semliki forest viruses with liposomes containing lipid-conjugated heparin. J. Virol. 76, 10128-10137 (2002).
324. Lee, E., Pavy, M., Young, N., Freeman, C., Lobigs, M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 69, 31-38 (2006).
325. Hidari, K. I. et al. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem. Biophys. Res. Commun. 376, 91-95 (2008).
326. Lim, S. P., Noble, C. G., Shi, P.-Y. The dengue virus NS5 protein as a target for drug discovery. Antiviral Res. 119, 57-67 (2015).
327. Poh, M. K. et al. A small molecule fusion inhibitor of dengue virus. Antiviral Res. 84, 260-266 (2009).